Elutia Inc. has announced a significant stock option grant to its Chief Financial Officer, Matthew Ferguson. This development, filed with the SEC on November 12, 2026, is crucial as it reflects the company's strategy to retain and motivate key executives amid a competitive landscape in the biological products industry.

Background

Elutia Inc. operates in the biological products sector, specifically under the SIC code 2836, which pertains to biological products (no diagnostic substances). The company is publicly traded on the Nasdaq under the ticker symbol ELUT. As a smaller reporting company, Elutia has been actively filing various forms with the SEC, including recent Form 4 submissions on November 12, 2026.

What the Filing Says

The SEC filing details that Matthew Ferguson was granted stock options for 446,000 shares of Class A Common Stock at an exercise price of $0.93 per share. The options were awarded on November 10, 2026, and will vest monthly over four years, with full vesting expected by November 9, 2030, contingent upon Ferguson's continued service.

Impact

This stock option grant may positively affect Elutia's management stability and align the interests of its executives with those of shareholders. Stakeholders, including employees and investors, may view this as a commitment to long-term growth and leadership continuity within the company.

What's Next

The filing does not say what happens next.